Search
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L49469] This approval was based on positive results demonstrated in the open-label, single-arm Phase 3 BENEGENE-2 study, where the annualized bleeding rate (ABR) was observed to be 1.3 for the 12 months
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalIf this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.
Picrotoxin
go.drugbank.com/drugs/DB00466ExperimentalA noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the gamma-aminobutyric acid-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and...
Bupivacaine
go.drugbank.com/drugs/DB00297ApprovedInvestigationalBupivacaine is a widely used local anesthetic agent.
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpar...
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalIn a large, randomized, open-label, multicenter, phase III trial, the treatment of mifamurtide in conjunction with three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate
Epinephrine
go.drugbank.com/drugs/DB00668ApprovedInvestigationalVet approvedEpinephrine, also known as adrenaline, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersen...
Vasopressin
go.drugbank.com/drugs/DB00067ApprovedInvestigationalVasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour. Vasopressin is v...
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalIn a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].
Elasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigational[L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29).